Early Signal Through Post-Approval Evidence
We work across the full development lifecycle, from early-stage translational strategy through Phase I-IV execution and federal public health research. What ties it together is access to patient populations that most organizations can't reach.
Translational Bridging & Evidence Strategy
We help sponsors, investigators, and federal partners identify evidence gaps early and design studies that hold up through both regulatory review and payer evaluation. Our work includes feasibility assessments, biomarker strategy, endpoint selection, and integrated evidence plans — grounded in 25M+ patient records from underserved communities. Therapeutic focus: oncology, rare disease, and infectious disease.
Clinical Trial Execution & Evidence Capture
Full-service CRO capabilities from pre-clinical through Phase II, with partnered Phase III/IV support. We cover protocol development, regulatory strategy, site management, safety monitoring, data management, and biostatistics. Our mobile clinical sites reach communities that traditional networks don't — and that's how we maintain 90% retention in hard-to-reach populations. Study types: Phase I-IV, interventional, observational, registry, post-market, and decentralized.
Federal Health & Public Health Research
We partner with federal agencies on infectious disease surveillance, biodefense, and community health initiatives. Our teams bring the same scientific rigor we apply in commercial programs, with experience in federal contracting and culturally informed engagement across underserved populations. Backed by 25M+ patient records, we help federal partners reach communities standard research often misses. SAM.gov registered · Federal contracting experience across HHS, CDC, DoD, and partnered agencies.
Better Evidence Starts With Better Data
When studies are designed on databases that underrepresent the patient population, the gaps show up later — in Complete Response Letters citing inadequate representation, in payer pushback on real-world applicability, and in label language that constrains commercial reach. Rubix LS starts with the data others don't have: 25M+ integrated patient records covering the populations, geographies, and disease presentations standard clinical databases miss.
The Scale Behind Our Work
Patient data sets integrated from underserved and underrepresented communities worldwide.
25M+
Trial retention rate in hard-to-reach populations, supported by mobile clinical sites and community-embedded research infrastructure.
90%
Research frameworks designed globally across oncology, rare disease, infectious disease, and public health.
50+
A Partner Built for Complex Programs
Integrated Teams, Not Handoffs
Your team stays consistent from study design through trial execution and data delivery. The scientists shaping your evidence strategy are connected to the operators running your trial.
Recent Work
See examples of how we design, execute, and scale evidence across therapeutic areas and program types, from investigator-led oncology studies to federal infectious disease programs.
Evidence That Moves Programs Forward
Every program we run generates the evidence that sponsors and federal partners need to move forward with confidence. Talk to our team about yours.